<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692783</url>
  </required_header>
  <id_info>
    <org_study_id>UFJ2008-19</org_study_id>
    <nct_id>NCT00692783</nct_id>
  </id_info>
  <brief_title>Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility</brief_title>
  <acronym>ICONIC</acronym>
  <official_title>Incidence of Oral Candidiasis, Prevalence of Candida Dubliniensis in HIV Patients and In-vitro Azole Susceptibility. (I.C.O.N.I.C.)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      C. dubliniensis has been identified as pathogen in Oropharyngeal Candidiasis(OPC)particularly
      among HIV patients. Azole therapy is a cornerstone in OPC, but resistance within C.
      dubliniensis isolates to diflucan is common.This is a prospective collection of biological
      specimens from oropharyngeal cavity with the purpose of determining the prevalence of C.
      dubliniensis in HIV/AIDS patients at the Duval County Department of Health Comprehensive care
      Center. It is hereto proposed an estimation of azole-resistance in these isolates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to try to establish the prevalence of C. dubliniensis as a causative organism
      of OPC in HIV and/or AIDS patients. We will aim to establish the resistance pattern for
      azoles but also for Flucytosine and amphotericin of these isolates.

      This study will serve as a support to previously published articles that have suggested
      intrinsic azole-resistance within this particular species of candida and we will try to
      postulate its possible correlation with clinical failure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Dr. Vindas completed his fellowship + low enrollment
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of oropharyngeal candidiasis in our HIV population; estimation of the prevalence of candida dubliniensis and pattern of azole resistance to direct future treatment</measure>
    <time_frame>April 2009</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Candidiasis</condition>
  <condition>HIV Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HIV with or without AIDS defining illnesses at the Boulevard Comprehensive Care Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient 18 years old or older with a documented diagnosis of HIV infection with or
             without AIDS-defining illnesses at the time of assessment, who is presenting with
             clinical symptoms and physical findings compatible with oropharyngeal candidiasis (as
             defined by the IDSA Guidelines for the Treatment and Management of HIV and HIV-
             related complications.

        Exclusion Criteria:

          -  Any prior diagnosis or established treatment for oropharyngeal, mucocutaneous or
             esophageal candidiasis documented in the patient's chart or any proven diagnosis based
             on reviews of physically available medical records and or history provided by patients
             that can be subject to later confirmation pertaining to the use of parenteral
             antifungals within 6 months prior to enrollment (azoles, echinocandins, amphotericin
             B, Flucytosine, etc).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Vindas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duval County Department of Health. Boulevard Comprehensive Care Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbiol. 1998 Feb;36(2):329-34. Review.</citation>
    <PMID>9466736</PMID>
  </results_reference>
  <results_reference>
    <citation>Milan EP, de Laet Sant' Ana P, de Azevedo Melo AS, Sullivan DJ, Coleman DC, Lewi D, Colombo AL. Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients. Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):29-35.</citation>
    <PMID>11687311</PMID>
  </results_reference>
  <results_reference>
    <citation>Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology. 1995 Jul;141 ( Pt 7):1507-21.</citation>
    <PMID>7551019</PMID>
  </results_reference>
  <results_reference>
    <citation>Sullivan DJ, Moran G, Donnelly S, Gee S, Pinjon E, McCartan B, Shanley DB, Coleman DC. Candida dubliniensis: An update. Rev Iberoam Micol. 1999 Jun;16(2):72-6.</citation>
    <PMID>18473572</PMID>
  </results_reference>
  <results_reference>
    <citation>Tintelnot K, Haase G, Seibold M, Bergmann F, Staemmler M, Franz T, Naumann D. Evaluation of phenotypic markers for selection and identification of Candida dubliniensis. J Clin Microbiol. 2000 Apr;38(4):1599-608.</citation>
    <PMID>10747150</PMID>
  </results_reference>
  <results_reference>
    <citation>Schorling SR, Kortinga HC, Froschb M, MÃ¼hlschlegel FA. The role of Candida dubliniensis in oral candidiasis in human immunodeficiency virus-infected individuals. Crit Rev Microbiol. 2000;26(1):59-68. Review.</citation>
    <PMID>10782340</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>candida</keyword>
  <keyword>dubliniensis</keyword>
  <keyword>candidiasis</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>azole resistance.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Candidiasis, Oral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

